Produit
AGENTS IA
APPLICATIONS DE L'IA
AUTRES
Solutions
SECTEURS D'ACTIVITÉ
USE CASES
Tarification
Ressources
EXPLORER
ENGAGER
ASSISTANCE ET SERVICES
À propos
Plateforme PatSnap Eureka
Mandataires en propriété intellectuelle
Agents pour l'ingénierie
Agents pour les sciences de la vie
Agents pour matériaux
PatSnap Eureka Desktop
NEWAnalytique
Intelligence IPSynapse
Renseignement biopharmaceutiqueBiographie
Recherche et analyse de séquences biologiquesChimique
Recherche et analyse de structures chimiquesPlateforme ouverte
NEWServices professionnels
Cabinets d'avocats
Sciences de la vie
Haute technologie
Competitor Tech Research
Design Risk Screening
Telecom SEP Claim Chart
Accès à plus de 2 000 000 000 points de données structurées dans les domaines des brevets, des sciences, des litiges et des technologies.
Innovez 75 % plus vite à un coût réduit de 25 %.
Cloud ou sur site pour une confidentialité et un contrôle maximaux
Reconnu par plus de 18 000 innovateurs à travers le monde
Pour l'utiliser, cliquez sur le bouton de vérification dans l'e-mail que nous avons envoyé à [email protected].
Cela contribue à sécuriser votre compte.
Vous devriez le recevoir sous peu. N'oubliez pas de vérifier votre dossier spam.
Unlock professional features and history
Already have an account? Log In
To start using PatSnap Eureka, click the verification button in the email we sent to .
This helps keep your account secure.
Haven't received it? Check your spam folder.
Série soigneusement sélectionnée offrant des informations précieuses aux professionnels de l'innovation.
Article | Rapport Prime editing's 2026 technology landscape: pegRNA engineering, off-target safety, 56,000 ClinVar variants, delivery bottlenecks, and the race to first-in-human trials.
Article | Rapport Spatial genomics maps gene expression to tissue locations, reshaping oncology, neuroscience and biodiversity. Explore the 2026 technology landscape and key innovation signals.
Article | Rapport Zilebesiran (ALN-AGT) targets hepatic AGT via GalNAc-siRNA to suppress RAAS upstream. Explore Phase 3 KARDIA data, IP landscape, and competitive threats in resistant hypertension.
Article | Rapport How AI-powered defect classification improves first-pass yield in PCB assembly inspection—covering AOI, deep learning, solder joint detection, and false-call reduction.
Article | Rapport A 2026 patent and literature landscape of autonomous vehicle HD map technology — covering map generation, V2X updates, interoperability, and AI-driven utilization.
Article | Rapport How engineers validate sealing integrity of implantable medical device enclosures under ISO 11607 sterile barrier requirements — methods, standards, and tools.
Article | Rapport CT-388 and petrelintide are competing in next-generation obesity pharmacotherapy. Explore the GLP-1/GIP dual agonist and amylin receptor agonist landscape, IP signals, and clinical race.
Article | Rapport A 2026 technology landscape of extracellular vesicle drug delivery: scaffold proteins, hybrid systems, CNS delivery, and the IP race shaping the field.
Article | Rapport Amycretin's Phase III launch signals a new era beyond semaglutide. Explore clinical data, patent IP, and competitive positioning of Novo Nordisk's dual agonist.
Article | Rapport 2026 landscape of floating offshore wind mooring technology: catenary, TLP, synthetic lines, shared anchors, and active repositioning patents analysed.
Article | Rapport How AI is transforming the way engineers monitor competitive patent filings in fast-moving tech sectors — from NLP classification to real-time alerts.
Article | Rapport Survodutide (BI 456906) is Boehringer Ingelheim's GLP-1/glucagon dual agonist challenging Lilly and Novo Nordisk in obesity. Explore the mechanism, pipeline, and competitive landscape.
Article | Rapport How generative AI, protein language models, and diffusion models are reshaping therapeutic antibody discovery in 2026 — key clusters, validated results, and strategic implications.
Article | Rapport Explore how engineers approach electromagnetic shielding for sensitive RF systems in dense mixed-signal PCB environments. Analysis, resources, and next steps.
Article | Rapport How AI-assisted synthesis route planning accelerates new chemical entity development in specialty chemicals — tools, workflows, and R&D strategy implications.